Colombo M P, Ferrari G, Stoppacciaro A, Parenza M, Rodolfo M, Mavilio F, Parmiani G
Division of Experimental Oncology D, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy.
J Exp Med. 1991 Apr 1;173(4):889-97. doi: 10.1084/jem.173.4.889.
We have investigated the effect of granulocyte colony-stimulating factor (G-CSF) delivery at the site of tumor growth by transducing, via retroviral vector, the human (hu) G-CSF gene into the colon adenocarcinoma C-26 and assaying the ability of transduced cells to form tumors when injected into syngeneic mice. As a control, the same tumor cells were infected with retroviruses engineered to transduce an unrelated gene, the human nerve growth factor receptor, or carry the neomycin resistance gene only. Only cells transduced with the huG-CSF were unable to develop tumors, although huG-CSF was expressed and produced at low level as estimated by both RNA analysis and enzyme-linked immunosorbent assay, indicating that G-CSF can exert an antitumor effect at a physiological dose. Implication of G-CSF as mediator of tumor inhibition was proven by reversing the nontumorigenic phenotype of G-CSF-expressing cells with anti-huG-CSF monoclonal antibody injected at the tumor site. No tumors were formed by injecting C-26 infected cells into nu/nu mice, while neoplastic nodules appeared after injection into sublethally irradiated mice; such tumors, however, regressed when mice normalized their leukocyte counts after irradiation. Tumors were also formed after injection of a mixture of infected and uninfected C-26 cells, although critical delay in tumor formation occurred when infected cells were 10 times more represented in the mixture. Histological examination of tissues surrounding the site of injection showed infiltration of neutrophilic granulocytes, whose number correlated with that of G-CSF-expressing C-26 cells in the injected mixture. These results indicate that G-CSF may have a potent antitumoral activity when released, even at low doses, at the tumor site. The antitumoral effect is mediated by recruitment and targeting of neutrophilic granulocytes to G-CSF-releasing cells.
我们通过逆转录病毒载体将人(hu)粒细胞集落刺激因子(G-CSF)基因转导至结肠腺癌C-26中,研究了在肿瘤生长部位递送G-CSF的效果,并检测了转导细胞注射到同基因小鼠体内形成肿瘤的能力。作为对照,相同的肿瘤细胞用经改造以转导无关基因(人神经生长因子受体)或仅携带新霉素抗性基因的逆转录病毒进行感染。尽管通过RNA分析和酶联免疫吸附测定估计huG-CSF表达并以低水平产生,但只有用huG-CSF转导的细胞无法形成肿瘤,这表明G-CSF能在生理剂量下发挥抗肿瘤作用。通过在肿瘤部位注射抗huG-CSF单克隆抗体逆转表达G-CSF细胞的非致瘤表型,证明了G-CSF作为肿瘤抑制介质的作用。将感染C-26的细胞注射到裸鼠中未形成肿瘤,而注射到亚致死剂量照射的小鼠中出现了肿瘤结节;然而,当小鼠在照射后白细胞计数恢复正常时,此类肿瘤消退。注射感染和未感染C-26细胞的混合物后也形成了肿瘤,尽管当混合物中感染细胞的比例高出10倍时肿瘤形成出现明显延迟。对注射部位周围组织的组织学检查显示有嗜中性粒细胞浸润,其数量与注射混合物中表达G-CSF的C-26细胞数量相关。这些结果表明,即使在肿瘤部位以低剂量释放,G-CSF也可能具有强大的抗肿瘤活性。抗肿瘤作用是通过嗜中性粒细胞募集并靶向到释放G-CSF的细胞来介导的。